Research Progress on Molecular Diagnosis and Individualized Treatment for Malignant Lymphoma
10.3971/j.issn.1000-8578.2023.23.0901
- VernacularTitle:恶性淋巴瘤的分子诊断及个体化治疗研究进展
- Author:
Ganggang WANG
1
;
Xianhuo WANG
;
Huilai ZHANG
Author Information
1. Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, the Sino-US Center for Lymphoma and Leukemia Research, Tianjin 300060, China
- Publication Type:Research Article
- Keywords:
Malignant lymphoma;
Molecular diagnosis;
Personalized medicine;
Research progress
- From:
Cancer Research on Prevention and Treatment
2023;50(12):1165-1173
- CountryChina
- Language:Chinese
-
Abstract:
Lymphoma refers to a group of heterogeneous malignancies originating from the reticuloendothelial and lymphatic systems. The clinical manifestations, treatment strategies, and disease outcomes of different types of lymphoma considerably vary. Recent developments in high-throughput sequencing technologies have enhanced understanding of the pathogenesis and molecular stratification of lymphoma. In the era of new drugs, precise stratification and targeted drug selection can not only improve the prognosis of patients with lymphoma but also reduce the toxic side effects of traditional chemotherapy, ultimately achieving the accurate diagnosis and individualized treatment of tumors. This article reviews the research progress of molecular diagnosis and individualized treatment of different lymphoma subtypes and lymphoma-related research in important meetings such as ASCO, EHA, and ICML in 2023.
